Email this article Structum therapy of patients with rheumatoid arthri-tis
- Authors: Shmidt Y.I1,2,3, Belozerova IV1,2,3, Akhmedzhanov FM1,2,3, Soldatov DG1,2,3
-
Affiliations:
- ГКБ № 1 им. Н. И. Пирогова
- Диагностический клинический центр № 1, Москва
- ЗАО "А/О Пьер Фабр", Москва
- Issue: Vol 79, No 11 (2004)
- Pages: 93-95
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29972
- ID: 29972
Cite item
Full Text
Abstract
Aim. To study efficacy of the chondroprotector chondroitin sulphate (structum, Pier Fabr Medicament
Production, France) in patients with rheumatoid arthritis (RA) and secondary osteoarthrosis of the
knee joints.
Material and methods. 15 women with a long history of RA (mean duration 11.9 years) entered an
open non-randomized trial of structum. The patients had a severe progressive highly active RA with a
definite x-ray stage of the disease. 13 patients had a positive rheumatoid factor (1:80 to 1:1280) and
involved knee joints which had been affected for 1 to 10 years (mean 5.3 years). The second x-ray
stage was in 8 patients, the third stage of knee joints arthrosis was in 7 ones. A marked pain syndrome
in the knee joints upon movement (mean 64.7 mm by VAS) was observed in all the examinees and at
rest (mean 28 mm by VAS) in 13 of 15 patients. Structum was given according to a standard scheme:
500 mg 3 times a day for 3 weeks than 500 mg 2 times a day for up to 6 months. Basic drugs for RA
were the same for all the observation period.
Results. Structum noticeably improved knee joint function (mean Leken's index 12.8, 11.3 and 9.4
scores before the treatment, on treatment month 3 and 6. Movement pain syndrome VAS reduced from
64.7 mm at the strart to 51 mm 3 months and 37.5 mm 6 months later, rest VAS - from 19 to 10.3
and 6.4 mm, respectively. The demand in intraarticular glucocorticoids went down from 52 injections
at the start of therapy to 6 after 6 months. Side effects for 6 months were absent. Overall efficacy was
good (73.3% and 80%) as judged by the doctors and patients, respectively. After 6 months of therapy
control x-rays found no progression of destructive changes in the knee joints (by MRI - in 4 patients).
Conclusion. Structum has a marked positive therapeutic effect in patients with severe and long-term
course of RA with associated pronounced secondary joint arthrosis.
Production, France) in patients with rheumatoid arthritis (RA) and secondary osteoarthrosis of the
knee joints.
Material and methods. 15 women with a long history of RA (mean duration 11.9 years) entered an
open non-randomized trial of structum. The patients had a severe progressive highly active RA with a
definite x-ray stage of the disease. 13 patients had a positive rheumatoid factor (1:80 to 1:1280) and
involved knee joints which had been affected for 1 to 10 years (mean 5.3 years). The second x-ray
stage was in 8 patients, the third stage of knee joints arthrosis was in 7 ones. A marked pain syndrome
in the knee joints upon movement (mean 64.7 mm by VAS) was observed in all the examinees and at
rest (mean 28 mm by VAS) in 13 of 15 patients. Structum was given according to a standard scheme:
500 mg 3 times a day for 3 weeks than 500 mg 2 times a day for up to 6 months. Basic drugs for RA
were the same for all the observation period.
Results. Structum noticeably improved knee joint function (mean Leken's index 12.8, 11.3 and 9.4
scores before the treatment, on treatment month 3 and 6. Movement pain syndrome VAS reduced from
64.7 mm at the strart to 51 mm 3 months and 37.5 mm 6 months later, rest VAS - from 19 to 10.3
and 6.4 mm, respectively. The demand in intraarticular glucocorticoids went down from 52 injections
at the start of therapy to 6 after 6 months. Side effects for 6 months were absent. Overall efficacy was
good (73.3% and 80%) as judged by the doctors and patients, respectively. After 6 months of therapy
control x-rays found no progression of destructive changes in the knee joints (by MRI - in 4 patients).
Conclusion. Structum has a marked positive therapeutic effect in patients with severe and long-term
course of RA with associated pronounced secondary joint arthrosis.
About the authors
Ye I Shmidt
ГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", МоскваГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", Москва
I V Belozerova
ГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", МоскваГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", Москва
F M Akhmedzhanov
ГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", МоскваГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", Москва
D G Soldatov
ГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", МоскваГКБ № 1 им. Н. И. Пирогова; Диагностический клинический центр № 1, Москва; ЗАО "А/О Пьер Фабр", Москва
References
- Алексеева Л. И., Архангельская Г. С., Давыдова А. Ф. и др. Отдаленные результаты применения структума (по материалам многоцентрового исследования). Тер. арх. 2003; 9: 82-86.
- Насонов Е. Л., Алексеева Л. И. Хондроитин сульфат (структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. Тер. арх, 2001; 11: 87-89.
- Шостак Н. А., Аксенова А. В., Правдюк Н. Г. и др. Боли нижней части спины при остеохондрозе позвоночника: опыт применения хондропротективного препарата. Тер. арх. 2002; 8: 67-69.
- Eugenio-Sarmiento R. М., Manapat В. Н. D., Salido E. О. The efficacy of chondroitin sulfate in the treatment of knee osteoarthritis: a meta-analysis. Osteoarthr. Cartilage 1999; 7 (suppi. A): abstr. 139.
- Leeb B. F., Schweitzer H., Montag K., Smolen J. S. A meta- analysis of chondroitin sulfate in treatment of osteoarthritis. Osteoarthr. Cartilage 1999; 7 (suppl. A): abstr. 130.
- Forslind K., Keller C., Hafstrom I., BARFOT Study Group. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J. Rheumatol. 2003; 30 (12): 2590-2596.
- O'Gradaigh D., Bord S., Ireland D., Compston J. E. Osteoclastic bone resorption in rheumatoid arthritis and the acute-phase response. Rheumatology 2003; 42 (11): 1429-1430.
- Yoshihara Y., Nakamura H., Obata K. et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 2000; 59 (6):455-461.
Supplementary files
